Company Overview and Recent Developments

BridgeBio Pharma (NASDAQ: BBIO) is a biotechnology company focused on developing treatments for genetic diseases and cancers. The company has recently transitioned into a commercial-stage biotech with its first FDA-approved drug, Attruby (acoramidis), for transthyretin amyloid cardiomyopathy (ATTR-CM) – a rare cardiac condition where abnormal proteins damage the heart (^[1]) (^[1]). Attruby was approved by the FDA in November 2024 and launched in the U.S., followed by European approval (branded Beyonttra in the EU) in February 2025 (^[1]) (^[1]). This marks a major milestone for BridgeBio, which until 2024 had financed its operations through equity and debt raises, asset sales, and collaborations without significant product revenue (^[1]).

The launch of Attruby/Beyonttra establishes a revenue stream for BridgeBio, but the company’s valuation remains largely tied to its pipeline prospects. Notably, BridgeBio’s encaleret, an oral therapy for Autosomal Dominant Hypocalcemia Type 1 (ADH1 – a rare genetic hypoparathyroid disorder), is in a fully enrolled Phase 3 trial with results expected in late 2025 (^[1]) (^[1]). The company also has late-stage candidates for achondroplasia (infigratinib, a low-dose FGFR inhibitor in Phase 3 for the most common form of dwarfism) and LGMD2I/R9 limb-girdle muscular dystrophy (BBP-418, with Phase 3 trial results anticipated in Fall 2025) (^[2]) (^[1]). These upcoming data readouts represent key catalysts that could significantly impact BridgeBio’s growth trajectory.

Shares of BridgeBio have performed strongly over the past year, reflecting optimism around its clinical successes. The stock is up about 95% year-over-year and recently neared a 52-week high (~$54) (^[3]) (^[3]). This momentum has caught analysts’ attention: UBS just raised its price target on BBIO from $72 to $82, reiterating a Buy rating (^[3]) (^[3]). UBS cites the upcoming Phase 3 data for encaleret in ADH1 as a “key catalyst,” calling ADH1 a “valuable and underappreciated pipeline asset” in BridgeBio’s portfolio (^[3]). In UBS’s view, the market has yet to fully price in encaleret’s potential. In fact, UBS increased its projected peak sales for encaleret in ADH1 from $700 million to $1 billion, and even added ~$600 million (at 50% probability) for potential use in broader hypoparathyroidism beyond ADH1 (^[3]). This more bullish forecast underpins the new $82 target, and UBS calls BridgeBio one of its “top picks,” expressing confidence in a successful Phase 3 outcome based on strong Phase 2 data and physician feedback on encaleret (^[3]).

Not only UBS, but the broader analyst community is optimistic. According to InvestingPro data, analysts have a strong bullish consensus on BBIO, with current price targets ranging from ~$41 on the low end to as high as $95 (^[3]) (^[3]). Multiple firms recently reiterated their positive stances ahead of encaleret’s Phase 3 readout – for example, TD Cowen (Buy, $60 PT) and Truist Securities (Buy, $66 PT) have highlighted encaleret’s promise and potential to improve on current care (^[3]). Jefferies and H.C. Wainwright also maintain Buy ratings in the $70 price-target range, reflecting broad confidence in BridgeBio’s pipeline prospects . In short, Wall Street sees significant upside if the company can execute on its late-stage programs – and UBS’s fresh $82 target underscores that investors don’t want to miss out on the next leg of BridgeBio’s story.

Dividend Policy and Yield

Despite its rising stock and new revenue stream, BridgeBio does not currently pay any dividend. In fact, the company has never paid cash dividends on its stock and explicitly does not intend to pay dividends for the foreseeable future (^[1]). Any shareholder returns thus far have come from share price appreciation, not income distributions. Moreover, BridgeBio’s debt covenants restrict it from paying dividends – under its financing agreements, the company is not permitted to declare or pay cash dividends while those debts are outstanding (^[1]). Consequently, BBIO’s dividend yield is 0%, and investors should not expect dividend income in the near term. Management’s focus is on reinvesting capital into R&D and product launches rather than returning cash to shareholders.

(Note: Metrics like Funds From Operations (FFO) or Adjusted FFO are not applicable here – those are used in REITs and cash-flow generating businesses. As a clinical-stage biotech turning commercial, BridgeBio’s cash flows are negative, and it does not report FFO/AFFO.)

Leverage, Debt Maturities and Coverage

BridgeBio’s capital structure carries substantial leverage, built up from years of funding R&D. As of year-end 2024, the company had about $1.7 billion in debt (^[1]). This included two large unsecured convertible note issues: $550 million of 2.50% Convertible Notes due 2027, and $747.5 million of 2.25% Convertible Notes due 2029 (^[1]). In addition, BridgeBio had a senior secured term loan facility (the “Financing Agreement”) with a principal balance of $450 million as of Dec 31, 2024 (^[1]). That term loan was a high-cost debt – carrying a 9% interest rate (with a portion payable in kind) – and it imposed restrictive covenants such as a ban on dividends and other limitations (^[1]). The interest burden was significant: this loan alone accounted for $51.5 million of cash interest in 2024 (^[4]), contributing to BridgeBio’s large annual net loss.

Importantly, in early 2025 BridgeBio took steps to strengthen its balance sheet and push out maturities. In February 2025, the company refinanced that $450 million term loan by issuing $500 million of new Convertible Senior Notes due 2031 (^[4]). The new 2031 notes carry just a 1.75% annual interest rate and were issued at a 45% conversion premium (meaning the conversion price is set ~45% above the stock’s level at issuance) (^[5]). The proceeds were used to fully repay and terminate the prior Financing Agreement loan (^[4]). This move eliminated near-term amortization payments and slashed interest expense, while significantly extending BridgeBio’s debt maturity profile (^[5]) (^[5]). By terminating the loan, BridgeBio also freed itself from the restrictive covenants that had limited its flexibility (^[4]). In management’s words, this long-term debt strategy “lowers interest expense, eliminates near-term payments, and significantly extends maturity” (^[5]) – a prudent deleveraging step as the company pivots to commercial operations.

After this refinancing, BridgeBio’s debt consists primarily of convertible notes maturing in 2027, 2029, and now 2031. The 2027 notes (2.5% coupon) and 2029 notes (2.25% coupon) remain in place, and the new 2031 notes (1.75% coupon) replace the term loan. The staggered maturities give BridgeBio some breathing room: no major principal repayments are due until 2027, by which time the company hopes to be generating substantial cash flow from multiple products. The annual interest burden has dropped markedly – from an estimated $80+ million in 2024 to roughly $39 million per year now (the sum of interest on all three convertible notes). This reduction, more than 50%, will save tens of millions in cash annually going forward (^[5]) (^[4]).

That said, coverage of these obligations is currently thin because BridgeBio is not yet profitable. Traditional interest coverage ratios (EBIT/Interest) are negative – the company’s operating losses exceed its interest costs, meaning it must use cash reserves (or new financing) to service debt. For example, in the latest quarter BridgeBio incurred an operating loss of $134 million (^[6]), far larger than the ~$10 million quarterly interest expense on its debt. This is an improvement from prior periods (the Q2 2025 operating loss narrowed from $175 million a year earlier) as revenue begins to offset costs (^[6]). But until earnings turn positive, debt service will rely on cash on hand rather than internal cash flows. The good news is that BridgeBio bolstered its liquidity with recent financings – it ended Q2 2025 with about $756.9 million in cash, equivalents and marketable securities (^[2]). Management stated this leaves the company “well capitalized” to continue the Attruby launch and to reach major clinical milestones in the coming year (^[2]). Indeed, BridgeBio expects its current cash is sufficient to fund operations for at least the next 12 months under its base plans (^[1]). In summary, while leverage is high, the near-term risk is mitigated by ample cash and pushed-out maturities. Investors should monitor how quickly BridgeBio’s new revenue can grow relative to its interest obligations, but the recent refinancing has significantly improved the debt profile.

It’s worth noting that due to heavy accumulated losses (over $2 billion since inception) and the large convertible debts, BridgeBio’s balance sheet shows a shareholders’ deficit – liabilities exceed assets under GAAP accounting (^[2]). This is not unusual for clinical-stage biotechs, but it underscores the need for successful product commercialization. Over time, if BridgeBio’s drugs generate substantial cash flow (or if debt is converted to equity), the balance sheet would strengthen. For now, credit risk remains a consideration – the company must keep executing on its pipeline and possibly raise additional capital before those big debt maturities if cash flows fall short.

Valuation and Growth Outlook

Valuing a company like BridgeBio is challenging using standard metrics. The firm is in the early innings of commercial sales and continues to post net losses, so traditional ratios like P/E or P/FFO are not meaningful (earnings and funds from operations are negative). Instead, investors and analysts value BBIO based on its product sales trajectory and pipeline potential. At the current stock price around $53–$54, BridgeBio’s market capitalization is roughly $10.2 billion (^[3]). This already bakes in significant expectations for growth, as it equates to a hefty multiple of the company’s present revenues. For example, in Q2 2025 – the first full quarter of Attruby sales – BridgeBio recorded $110.6 million in revenue (^[2]). Annualizing that run-rate would be ~$442 million, implying a Price-to-Sales (P/S) multiple over 20×. Such a high multiple reflects the fact that investors expect revenues to ramp dramatically in coming years (from both Attruby and future product launches).

Looking at Attruby/Beyonttra (acoramidis), analysts are quite bullish about its long-term prospects. This drug targets ATTR-CM, a disease affecting an estimated 300,000–500,000 patients worldwide (^[1]) (with >100,000 in the U.S. alone if including wild-type and hereditary cases). Pfizer’s Vyndaqel (tafamidis) has been the dominant therapy, with global sales exceeding $2 billion annually, but acoramidis enters as a potentially best-in-class treatment (^[6]) (^[1]). BridgeBio priced Attruby at roughly $18,759 for a 28-day supply, which is about ~$245,000 per year – slightly below Vyndaqel’s ~$268,000 annual cost (^[7]). In pivotal trials, acoramidis significantly improved cardiovascular outcomes (reducing hospitalizations and deaths combined), although the treatment did not achieve a statistically significant benefit on all-cause mortality alone (^[7]). Some experts expect the established presence of Pfizer’s drug and its proven survival benefit to pose a commercial challenge for Attruby initially. Indeed, Reuters reported that analysts anticipate “limited initial uptake” of acoramidis due to competition from Pfizer’s entrenched once-daily pill (^[7]). This cautious view on near-term market share might explain why BridgeBio has partnered with pharma heavyweights for overseas markets – Bayer in Europe and Alexion (AstraZeneca’s rare-disease unit) in Japan – to help drive adoption (^[7]). Those partnerships also provided BridgeBio with milestone payments (for example, a $30 million milestone was earned in Q2 2025 upon Japanese pricing approval of Beyonttra (^[2])).

Despite a potentially slow start, the consensus outlook for acoramidis is very robust. By 2030–2035, analysts project acoramidis could achieve blockbuster status. In fact, forecasts peg peak sales around $2.5 billion by 2035 for acoramidis (^[7]). If BridgeBio can realize that level of revenue, it would justify a large portion of the company’s current valuation (for context, a $2.5B revenue at a typical biotech sales multiple of ~5× could be worth $12.5B in enterprise value). Importantly, these projections assume that acoramidis will gain significant market share over time thanks to its near-complete TTR stabilization (Attruby is the first therapy shown to achieve ≥90% TTR stabilization, which could translate into superior clinical benefits) (^[1]) (^[1]). The drug’s approvals in both U.S. and EU also open multiple reimbursement channels, and physicians are gaining experience with it – by August 2025, over 3,700 unique patient prescriptions had already been written in the U.S. in the initial launch phase (^[2]). As the sales force continues to educate cardiologists and more real-world data emerges, BridgeBio could see an acceleration in uptake, especially if acoramidis proves its value in broader patient subsets (such as earlier-stage ATTR-CM or patients intolerant to Pfizer’s drug).

Beyond acoramidis, encaleret represents the next big value driver on the horizon. UBS’s recent analysis gives a glimpse of how the Street is valuing this asset: after updating its model for encaleret, UBS added roughly $300+ million in expected annual peak sales (raising the forecast from $700M to $1B in ADH1) and assigned a 50% probability to another $600M in potential sales for other hypoparathyroidism indications (^[3]). This implies that, in UBS’s risk-adjusted NPV, encaleret’s current value to the stock shot up – hence the price target boost to $82. If encaleret’s Phase 3 CALIBRATE trial reads out positively (data due in 2H 2025), it could lead to regulatory approval as the first targeted therapy for ADH1 (^[1]) (^[1]). ADH1 affects a small patient population (~12,000 people in the U.S., of whom ~9,000 are symptomatic) (^[3]), but encaleret’s clinical data so far have been excellent – Phase 2 results showed 92% of patients achieved normal blood calcium without supplements, and the drug was well-tolerated (^[1]). If those results translate into Phase 3, encaleret could quickly become the standard of care for ADH1 and possibly be used off-label in related calcium disorders. That would open the door to the broader hypoparathyroidism market (much larger than ADH1 alone), which is why UBS sees substantial undervalued optionality in this program (^[3]) (^[3]).

In terms of valuation comps, BridgeBio is often compared to other late-stage biotechs with new rare-disease drugs. Companies like Alnylam (ALNY) or Ionis (IONS) – which have or are launching ATTR and genetic disorder therapies – trade at high revenue multiples due to pipeline value. BridgeBio’s ~$10B market cap is in a similar ballpark to some of these peers when they had one approved product plus pipeline. For example, Alnylam (with RNAi drugs for ATTR polyneuropathy and other conditions) traded around 10–15× sales during its early launch phase, reflecting investor willingness to pay up for platform potential. BridgeBio’s current EV/sales might appear high (>20× 2025 sales), but if one incorporates probability-weighted revenue from encaleret, infigratinib (achondroplasia), BBP-418 (LGMD2I), and others, the forward multiples are much more reasonable. Essentially, the market is valuing BridgeBio on a sum-of-the-parts pipeline NPV. UBS’s $82 target, for instance, suggests a market cap of ~$15 billion, which presumably corresponds to successful execution of encaleret plus continued growth of acoramidis (and perhaps modest credit for the achondroplasia program). That would still be below the high end of analyst scenarios – recall some bullish targets go up to $95/share (^[3]), which likely factor in additional pipeline success (e.g. positive Phase 3 for achondroplasia, etc.). On the other hand, the lowest targets around $40–$45 likely assume a more conservative view where encaleret or other programs might stumble (^[3]). In summary, upside valuation rests on executing the pipeline to reach multi-billion-dollar revenues by late this decade, while downside could materialize if key programs fail (in which case the stock could retreat toward the value of acoramidis alone, which might not support a $10B valuation by itself in the near term).

Risks, Red Flags, and Considerations

Investing in BridgeBio entails significant risks common to biotech, as well as some company-specific red flags. Here are key factors to weigh:

– Clinical and Regulatory Risk: The company’s bull case hinges on successful clinical trial outcomes for its pipeline. Any failure or delay in Phase 3 trials (encaleret for ADH1, BBP-418 for LGMD2I, infigratinib for achondroplasia) could severely hurt the stock. BridgeBio has experienced setbacks before – for instance, earlier interim data for acoramidis in 2021 raised doubts and led to a stock plunge before the final trial succeeded. Future trials may not all be positive. Even if trials meet endpoints, there’s regulatory risk (FDA or EMA might require additional data or impose restrictions). Bottom line: The pipeline’s unproven nature means binary outcomes that could swing the valuation drastically.

– Commercial Execution and Competition: BridgeBio is new to commercializing a drug, and its initial product faces stiff competition. Pfizer’s Vyndaqel has a strong foothold in ATTR-CM; convincing physicians to switch to Attruby will take time. Analysts warn that early uptake of acoramidis could be modest (^[7]), and payors might also scrutinize its high price. Moreover, Alnylam’s vutrisiran (an RNAi therapeutic) was approved in 2025 for ATTR-CM and will provide additional competition (^[1]). For achondroplasia, BioMarin’s injectable Voxzogo is already approved, meaning BridgeBio’s infigratinib will need to show superior convenience or efficacy in children. In short, market share may be hard-won, and if BridgeBio’s commercial team underperforms, revenue could lag expectations. The company’s heavy SG&A investments (nearly $70M YoY increase in Q2 2025 to build out sales infrastructure (^[6])) underscore the challenge ahead – and if sales disappoint, those costs will weigh heavily.

– Financial Losses and Cash Burn: BridgeBio continues to operate at a significant net loss, and will likely remain unprofitable for the next couple of years. In the first half of 2025, operating losses were ~$239 million (^[6]) (^[6]), as the company ramped up spending for the Attruby launch and ongoing R&D. While it has ~$757 million in cash as of mid-2025 (^[2]), the current burn rate could deplete that in ~2 years if not offset by growing revenue. The company may need to raise additional capital (via equity or partnerships) if its cash runway diminishes before reaching self-sustaining cash flow. Such financings could dilute existing shareholders or add debt. BridgeBio’s accumulated deficit and even a stockholders’ equity deficit on the balance sheet (^[2]) highlight the financial risk if revenues don’t scale up as hoped.

– Leverage and Convertible Debt Overhang: As discussed, BridgeBio carries ~$1.8 billion in debt. While maturities are staggered and interest costs are much lower after refinancing, this debt still represents a claim on the company’s future. If the share price does not appreciate sufficiently by 2027–2029, holders of the convertible notes might opt for cash repayment instead of converting to equity. Refinancing those notes at maturity could be costly or difficult if market conditions or company prospects deteriorate by then. On the flip side, if the notes do convert (the 2027 notes are already in the money with a ~$42.71 conversion price (^[1]) (^[1])), shareholders will face dilution. In total, full conversion of all notes could add roughly 25–30 million new shares (about 15% dilution vs. ~196 million shares issued as of end-2024 (^[1])). While this is a manageable dilution for a successful growth story, it’s something for investors to keep in mind. The presence of capped call transactions that BridgeBio purchased (at strike prices around $42.71 for 2027 notes and $97.04 for 2029 notes) will offset some dilution up to those price levels (^[1]) (^[1]), but not beyond. In summary, debt is both a tool and a ticking clock for BridgeBio – the company must execute before the bills come due.

– Regulatory and Safety Hurdles: Even after approval, BridgeBio’s products will be subject to ongoing regulatory oversight. For example, the FDA could require post-marketing studies for acoramidis to confirm long-term benefits. Any safety signals could limit the drug’s use. The patient populations BridgeBio serves are small and sometimes fragile; unforeseen adverse effects in broader use could emerge. Additionally, the pricing of six-figure therapies for rare diseases might invite payer pushback or regulatory scrutiny. If insurers impose strict prior authorizations or if health systems balk at the cost, BridgeBio might have to offer steeper discounts or face slower uptake. There’s also the risk of legislative changes around drug pricing (in the U.S. or abroad) that could cap prices on treatments like these in the future.

– Execution and Organizational Risk: BridgeBio is juggling a lot of moving parts – launching a major cardio drug, running multiple Phase 3 trials, and managing collaborations. As a relatively young company (founded in 2015, IPO in 2019), it doesn’t have a long track record of large-scale execution. There could be growing pains, whether it’s in manufacturing enough supply (they rely on third-party manufacturers like CMOs for production (^[1]) (^[1])), scaling up a global marketing presence (hence partnering with Bayer/Alexion), or prioritizing which pipeline programs to advance (they have dozens of preclinical projects as well). Any missteps – e.g. a manufacturing delay, a trial enrollment slowdown, or loss of key personnel – could pose setbacks. Investors should watch gross margins and operating expenses in upcoming quarters to see how efficiently BridgeBio is handling its expansion.

Despite these risks, it’s worth emphasizing that BridgeBio’s strategy of focusing on high-value rare diseases has, so far, paid off with a major drug approval and a rich pipeline. The upside potential (if pipeline drugs succeed and revenues ramp up) is the reason analysts are bullish. However, the downside risks (if clinical results disappoint or commercialization falters) are significant given the company’s leveraged and cash-hungry position (^[1]) (^[1]). This makes BBIO a higher-volatility investment suitable for those with a tolerance for biotech risk. Prudent investors will keep an eye on each catalyst and quarterly result as the story unfolds.

Open Questions and What to Watch

As BridgeBio navigates the next 12–18 months, a few open questions will likely determine whether UBS’s bullish thesis plays out or not:

– Will encaleret’s Phase 3 results meet expectations? The data due in late 2025 for encaleret in ADH1 is arguably the most anticipated catalyst. UBS and others are optimistic (^[3]), but until the trial reads out, there is uncertainty. A strong positive result could unlock a first-in-class approval by 2026 and cement encaleret as a second commercial pillar for BridgeBio. On the other hand, any disappointment (efficacy short of Phase 2, safety issues, etc.) would raise doubts about a key leg of the growth story. Investors should watch for the CALIBRATE Phase 3 topline data and subsequent FDA filing updates. This will answer if UBS’s $1 billion peak sales forecast for encaleret is realistic, or if adjustments are needed.

– How rapidly can Attruby/Beyonttra gain market share in ATTR-CM? Early prescription numbers show an encouraging launch (3,751 patient prescriptions in ~8 months) (^[2]), but the real test will be how acoramidis competes against Pfizer’s standard. Will cardiologists switch stable patients to Attruby? Can BridgeBio expand diagnoses of ATTR-CM (many patients remain undiagnosed) to grow the overall pie? Also, Alnylam’s RNA-based therapy for ATTR-CM was approved in 2025, potentially offering an alternative for some patients. Over the next few quarters, revenue trends and management commentary should reveal Attruby’s traction. If sales ramp faster than expected, the stock could respond very positively; if uptake is slow (as some analysts warned (^[7])), BridgeBio’s near-term valuation might come under pressure. Keep an eye on quarterly product revenue figures and market-share metrics relative to Vyndaqel.

– Can BridgeBio effectively handle multiple product launches and trials simultaneously? By 2026, the company could be in a position of launching several products in different therapeutic areas (cardiology, endocrinology, genetically-driven pediatrics, etc.). It already has partnerships in place for international marketing of acoramidis (^[7]); will it seek similar partners for encaleret or others, or build its own global infrastructure? Additionally, manufacturing and supply chain robustness will be tested as volumes grow (^[1]) (^[1]). BridgeBio’s ability to manage these operational challenges is still unproven at large scale. This raises questions: Will the company need to raise more capital or perhaps consider strategic partnerships (or even an acquisition by a larger pharma) to fully realize the potential of its pipeline? Any signals on partnering of the achondroplasia program or others (similar to the Bayer/Alexion deals) will be telling. Investors should also watch R&D spend and SG&A trends – are costs coming under control as revenues rise, indicating economies of scale, or are they continuing to climb steeply?

– How will BridgeBio navigate its financial inflection point? With ~$750M in cash and a reduced-interest debt load, the company has a decent runway, but it’s still burning cash. The core question is: can BridgeBio reach a self-sustaining financial model before needing another big funding round? If acoramidis and encaleret hit stride by 2026–2027, the combined revenue might approach a scale to cover operating costs. However, if there are hiccups, the company might need to tap the markets again. Any such dilution or new debt could affect the risk/reward profile. Also, by 2027 the $550M convertible notes come due – ideally, the stock would be well above $42 so that converts to equity smoothly, but if not, management might face a refinancing. This raises an open question: Will the pipeline success translate into a high enough stock price to ease the debt overhang? A stock comfortably above the conversion prices (e.g. >$97 by 2029 for the later notes (^[1])) would mean debt essentially turns into equity without cash outlay. If the stock languishes, the debt could remain a burden. Thus, the trajectory of BBIO’s share price (driven by trial outcomes and sales) will indirectly determine how that balance sheet risk resolves. Investors should watch for any early moves by BridgeBio to manage debt – for instance, if the stock runs up, will they consider calling or converting the 2027 notes early or buying back some debt? Likewise, any guidance on cash burn vs. cash on hand in upcoming earnings will inform whether further financing might be needed.

In conclusion, BridgeBio offers a high-risk, high-reward proposition. UBS’s bold $82 target underscores the belief that the stock is undervalued relative to its pipeline – essentially urging investors not to “miss out” on the opportunity. The pieces are in place: a newly approved drug with multi-billion potential, a promising late-stage pipeline, and a shored-up capital structure. However, executing on that promise is the hard part. As we’ve detailed, there are numerous hurdles and unknowns that could change the narrative for better or worse. Investors should stay tuned to the data announcements, product uptake trends, and management’s moves. If BridgeBio delivers on the upcoming milestones, the current stock price could indeed look like a bargain in hindsight – but failure to deliver would make UBS’s optimism look overly rosy. With catalysts on the near-term horizon, the next year will be pivotal in determining whether BBIO can justify the bulls’ confidence. Don’t miss out on watching this story unfold, but proceed with a balanced understanding of the risks involved.

Sources:

1. BridgeBio Pharma 2024 10-K – Dividend policy (no cash dividends) (^[1]) 2. BridgeBio Pharma 2024 10-K – Debt summary ($550M 2027 notes, $747.5M 2029 notes, $450M term loan) (^[1]) (^[1]) 3. BridgeBio Press Release (Feb 24, 2025) – Announcing $500M convertible notes due 2031 to refinance term debt (^[4]) (^[4]) 4. BridgeBio Press Release (Feb 26, 2025) – Pricing of $500M notes (1.75% rate, 45% premium) and use of proceeds (^[5]) (^[5]) 5. BridgeBio Q2 2025 Results (Aug 5, 2025) – Revenue $110.6M, Attruby $71.5M, milestone $30M from Alexion (^[2]) (^[2]) 6. BridgeBio Q2 2025 Results – Operating loss $134M; SG&A up $69.6M for launch (^[6]) (^[6]) 7. BridgeBio Q2 2025 Results – Cash $756.9M as of 6/30/25 (well-capitalized per company) (^[2]) 8. Reuters – FDA approval of Attruby (Nov 2024), pricing vs. Pfizer, analysts see $2.5B peak sales by 2035 (^[7]) (^[7]) 9. Investing.com/StreetInsider – UBS raises BBIO target to $82 on encaleret optimism (Sep 2025), details on ADH1 sales assumptions (^[3]) (^[3]) 10. Investing.com – Analyst consensus bullish (targets $41–$95) (^[3]); other analyst targets (Cowen $60, Truist $66, Jefferies $70, etc.) (^[3]) 11. BridgeBio 2024 10-K – Encalaeret Phase 3, orphan designation, Phase 2 results (^[1]) (^[1]) 12. BridgeBio 2024 10-K – Attruby (acoramidis) FDA and EC approval, launch details (^[1]) (^[1]) 13. BridgeBio 2024 10-K – Attruby efficacy (ATTRibute-CM trial results) (^[1]) and competition (Pfizer’s tafamidis, Alnylam’s vutrisiran) (^[1]).

Sources

1. https://fintel.io/doc/sec-bridgebio-pharma-inc-1743881-10k-2025-february-20-20139-4344
2. https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Second-Quarter-2025Financial-Results-and-Business-Updates/default.aspx
3. https://uk.investing.com/news/analyst-ratings/bridgebio-pharma-stock-price-target-raised-to-82-from-72-at-ubs-93CH-4261626
4. https://investor.bridgebio.com/news/news-details/2025/bridgebio-initiates-long-term-debt-management-strategy-and-announces-proposed-offering-of-convertible-senior-notes-to-refinance-senior-secured-debt-02-24-2025/default.aspx
5. https://investor.bridgebio.com/news/news-details/2025/bridgebio-prices-offering-of-500-million-convertible-senior-notes-due-2031-to-refinance-senior-secured-debt-02-26-2025/default.aspx
6. https://biospace.com/press-releases/bridgebio-reports-second-quarter-2025-financial-results-and-business-updates
7. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bridgebios-drug-rare-heart-condition-2024-11-23/

For informational purposes only; not investment advice.